Licensed vs Certified Peptides: What Those Words Actually Mean

Almost every peptide vendor describes itself using one of four terms. None of them is regulated in the way buyers assume, and the differences between them are the difference between a meaningful claim and a decorative one.

The four claims, ranked by what they actually establish

"FDA registered" is the one to watch

Facility registration is an administrative filing. A facility that manufactures, processes or packs drugs registers with FDA and receives a registration number. That is the whole process.

• It is not an inspection. Registration precedes inspection and does not imply one occurred.

• It is not approval. FDA approves drug products, not facilities.

• It is not an endorsement. FDA states explicitly that registration does not denote approval.

• It says nothing about the product. A registered facility can produce a research-use-only peptide that has no approval of any kind — which is the situation for essentially every peptide sold this way.

The FDA-approved peptides list sets out what approval actually looks like, and how few research peptides have it.

cGMP: the one with real content

Current Good Manufacturing Practice is a genuine set of quality-system requirements — documented procedures, validated processes, controlled materials, batch records, deviation handling. A facility genuinely operating to cGMP is doing something substantive.

The gap is between “cGMP facility” and “this product was made under cGMP”. A facility can hold a cGMP-compliant line for one customer and run research-grade synthesis elsewhere. The claim that matters is product-level, not facility-level.

"Pharmaceutical grade" — a term with no definition

There is no regulatory definition of pharmaceutical grade for peptides. In some contexts it loosely means meeting a pharmacopoeial monograph — a USP or EP standard for a specific substance. Most research peptides have no monograph, so there is no standard to meet and the phrase describes nothing.

RUO is the row worth understanding. It is not a quality tier. It is a statement that the product is not for human or veterinary use, and it is the designation under which essentially all research peptides are sold.

What to verify instead

Replace the four adjectives with four checks that produce evidence:

1. A batch-specific COA. The batch number on the certificate must match the number on the vial. A single COA reused across products or batches proves nothing about what you hold. See the COA guide.

2. Mass spectrometry, not just HPLC. HPLC purity says how much of the sample is one thing. Mass spectrometry says whether that thing is the peptide claimed. A vendor supplying only HPLC has not established identity.

3. A named testing laboratory. “Third-party tested” without the laboratory’s name is unverifiable by design. A named lab can be contacted.

4. Consistency across batches. Purity figures that are identical to the decimal place across every batch are a formatting artefact, not a measurement.

The compounding pharmacy claim

Some vendors describe peptides as compounded or pharmacy-sourced. For most research peptides this claim cannot be legitimate: FDA placed a group of widely sold peptides — including BPC-157, ipamorelin, CJC-1295, epitalon, kisspeptin-10, MOTS-c and thymosin beta-4 — into Category 2 for bulk drug substances, meaning compounding pharmacies cannot legally prepare them.

A “compounded BPC-157” offer therefore describes something that should not exist through legitimate channels. That is a stronger signal than any positive claim on the same page.

Reading a vendor page in two minutes

The vendor selection guide expands this into a full evaluation process, and the legality guide covers the regulatory position these claims sit inside.